BIOHAVEN OPTIMISTIC FOR NEXT PHASE OF TRIAL DESPITE DISAPPOINTING TOPLINE DATA As NAF previously reported, BioHaven Pharmaceutical Holding Company Ltd. recently completed its 8-week trial of dosing for its drug compound Read More…
Registration for 2024 Annual Ataxia Conference is NOW OPEN! Early-bird discount available for a limited time. LEARN MORE!